Drug Trial Radar · NCT00358176
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Dec 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,231
Actual
Start
Jul 2004
Primary completion
Mar 2007
Study completion Mar 2007
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Procter and Gamble
- First posted
- Jul 31, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar spine in postmenopausal women with osteoporosis. To confirm the efficacy of 75 mg risedronate tablets taken on 2 consecutive days per month in postmenopausal women with osteoporosis in increasing bone mass in proximal femur, femoral neck and femoral trochanter and decreasing bone resorption. To confirm general safety of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate taken daily.
Conditions
- Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in lumbar spine bone mineral density (BMD) at
- Month 12 measured by dual-energy X-ray absorptiometry (DXA).
Locations
11 sites in 11 countries. Site status is shown where the registry gives one.
Sanofi-Aventis
Bridgewater, New Jersey
Sanofi-Aventis
San Isidro, Argentina
Sanofi-Aventis
Macquarie Park, Australia
Sanofi-Aventis
Laval, Canada
Sanofi-Aventis
Prague, Czechia
Sanofi-Aventis
Paris, France
Sanofi-Aventis
Beirut, Lebanon
Sanofi-Aventis
Warsaw, Poland
Sanofi-Aventis
Midrand, South Africa
Sanofi-Aventis
Istanbul, Turkey (Türkiye)
Sanofi-Aventis
Guildford Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.